Loading company…
Weilai develops pediatric medicines, with a focus on neonatal and critical care.
Weilai develops medicines for neonatology, pediatric critical care, and respiratory conditions. Its products include jingtian qinglong capsule, low molecular weight heparin sodium injection, and Rebas® dopamine hydrochloride for injection. Established in 2014, the company is based in Hefei, China. In May 2023, it received strategic investment from Chuangyu Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in